CXCR4 antagonist BL-8040 in a recent phase I clinical study (NCT02073019) besides highly efficient mobilization of pluripotent hematopoietic progenitors showed also superior yields of CD4+ and CD8+ T cells, NKT, NK, and DCs, suggesting increased engraftment ability of CXCR4 mobilized populations, a higher anti-tumor effect and faster immune reconstitution potential. Here, CD4 is linked to neoplasm.